NorthCrest Asset Manangement’s Vir Biotechnology VIR Stock Holding History

NorthCrest Asset Manangement’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,700	Closed	-$87.6K	–	583
2024 Q3	$87.6K	Hold	11,700	–	–	﹤0.01%	545
2024 Q2	$104K	Hold	11,700	–	–	﹤0.01%	508
2024 Q1	$119K	Sell	11,700 -200	-2%	-$2.04K	﹤0.01%	496
2023 Q4	$120K	Hold	11,900	–	–	﹤0.01%	504
2023 Q3	$112K	Hold	11,900	–	–	﹤0.01%	492
2023 Q2	$292K	Sell	11,900 -400	-3%	-$10K	0.01%	447
2023 Q1	$286K	Buy	12,300 +900	+8%	+$23K	0.01%	445
2022 Q4	$289K	Buy	11,400 +800	+8%	+$19.6K	0.02%	357
2022 Q3	$204K	Hold	10,600	–	–	0.01%	419
2022 Q2	$270K	Hold	10,600	–	–	0.01%	388
2022 Q1	$273K	Buy	10,600 +200	+2%	+$5.93K	0.01%	369
2021 Q4	$435K	Buy	+10,400	New	+$407K	0.02%	327

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

NorthCrest Asset Manangement's VIR Position: Q4 2024 in Review

NorthCrest Asset Manangement sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 11,700 shares — an estimated $87.6K sold.

NorthCrest Asset Manangement first reported a position in VIR in Q4 2021 and held it in 12 quarters. The position peaked at $435K in Q4 2021. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

NorthCrest Asset Manangement reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
NorthCrest Asset Manangement sold 11,700 Vir Biotechnology shares in Q4 2024, an estimated $87.6K.
NorthCrest Asset Manangement first reported a position in Vir Biotechnology in Q4 2021 and held it in 12 quarters.
NorthCrest Asset Manangement's Vir Biotechnology position peaked at $435K in Q4 2021.
208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on NorthCrest Asset Manangement's 13F filing for Q4 2024, filed 10 Jan 2025.